Minutes of the fiftieth meeting on 24 March 2021 (via audio conference) adopted by the ECDC Management Board at its fifty-second meeting on 16 June 2021.
This document provides guidance on diagnostic testing, molecular characterisation and metagenomic analysis for suspect cases of severe acute hepatitis of unknown aetiology.
Due to its propensity to cause outbreaks and its antifungal resistance, C. auris poses a risk for patients in healthcare facilities in Europe. Difficulties with laboratory identification, combined with a lack of awareness of this new Candida species, might result in unnoticed outbreaks. There is a clear need to raise awareness in European healthcare facilities in order adapt laboratory testing strategies and implement enhanced control measures to prevent further hospital outbreaks.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 6-12 November 2016 and includes updates on Zika virus, measles and influenza.
This document outlines the public health considerations for the use of self-tests to detect SARS-CoV-2 by public health authorities in the European Union/European Economic Area (EU/EEA). Only rapid antigen detection tests (RADTs) for self-testing for direct detection of SARS-CoV-2 virus particles in infectious individuals are considered within this document.